Haemophilic patients with inhibitors to factor VIII or IX: variables affecting treatment response.
about
Optimization of factor VIII replacement therapy: can structural studies help in evading antibody inhibitors?Gene therapy ethics and haemophilia: an inevitable therapeutic future?A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance.Enhancement of the enzymatic activity of activated coagulation factor IX by anti-factor IX antibodies.An antibody specific for coagulation factor IX enhances the activity of the intrinsic factor X-activating complex.
P2860
Haemophilic patients with inhibitors to factor VIII or IX: variables affecting treatment response.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Haemophilic patients with inhi ...... affecting treatment response.
@ast
Haemophilic patients with inhi ...... affecting treatment response.
@en
Haemophilic patients with inhi ...... affecting treatment response.
@nl
type
label
Haemophilic patients with inhi ...... affecting treatment response.
@ast
Haemophilic patients with inhi ...... affecting treatment response.
@en
Haemophilic patients with inhi ...... affecting treatment response.
@nl
prefLabel
Haemophilic patients with inhi ...... affecting treatment response.
@ast
Haemophilic patients with inhi ...... affecting treatment response.
@en
Haemophilic patients with inhi ...... affecting treatment response.
@nl
P2860
P1433
P1476
Haemophilic patients with inhi ...... affecting treatment response.
@en
P2093
P2860
P304
P356
10.1046/J.1365-2516.2001.00473.X
P577
2001-01-01T00:00:00Z